Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00631059 · ClinicalTrials.gov registry record · NA
Assessment and Determination of Chemotherapy Resistance in Newly-Diagnosed or First Relapse Leukemia Patients
A NA study, sponsored by University of California, Irvine.
- Terminated
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT00631059 is a NA study that was terminated before completion, run by University of California, Irvine. The registered enrollment target is 40 participants.
The verdict
NCT00631059, a NA study, was terminated before completion, sponsored by University of California, Irvine.
- TERMINATED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
The objective of this protocol is to collect leukemia cell specimens from adults (18 years of age) diagnosed with acute leukemia at time of initial diagnosis and, if applicable, at time of first relapse. These specimens, in conjunction with a de-identified data set, will be utilized prospectively to determine potential chemotherapy resistance in this patient population. The specific aims of this study are as follows: To collect peripheral blood specimens from patients diagnosed with acute leukemia at time of initial diagnosis and, if applicable, at time of first relapse To evaluate the leukemia cells in the blood specimens for chemotherapy resistance utilizing the Hem(A)+ technology To develop a body of evidence from acute leukemia patients that demonstrates the applicability of the Hem(A)+ assay to determine the following: Predict responders and non-responders to common chemotherapeutic agents Track treatment results and comparison to prediction results from the assay Identify optimal chemotherapy doses for each patient Identify the most efficacious pharmaceutical agent combinations
Interventions
- OTHER Hem(A)+ Technology
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-03 |
| Est. Completion | 2010-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00631059
The ClinicalTrials.gov registry entry for NCT00631059 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hem(A)+ Technology is the first listed.
NCT00631059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00631059 about?
NCT00631059 is a clinical study titled "Assessment and Determination of Chemotherapy Resistance in Newly-Diagnosed or First Relapse Leukemia Patients". The objective of this protocol is to collect leukemia cell specimens from adults (18 years of age) diagnosed with acute leukemia at time of initial diagnosis and, if applicable, at time of first relapse. These specimens, in conjunction with a de-identified data set, will be utilized prospectively to...
What is the current status of trial NCT00631059?
This trial is currently terminated. It is a NA study. The enrollment target is 40 participants. The study started on 2008-03. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00631059?
The interventions under investigation include: Hem(A)+ Technology (OTHER).
Who is sponsoring clinical trial NCT00631059?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.